
STAAR Surgical Company STAA
$ 23.49
-2.65%
Quarterly report 2025-Q3
added 11-05-2025
STAAR Surgical Company Deferred Revenue 2011-2025 | STAA
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue STAAR Surgical Company
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 3.75 M | - | 1.28 M | 1.24 M | 439 K | 596 K | 373 K | - | 187 K | 152 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.75 M | 152 K | 1 M |
Deferred Revenue of other stocks in the Medical instruments industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
BioLife Solutions
BLFS
|
103 K | $ 24.56 | 0.7 % | $ 1.13 B | ||
|
Baxter International
BAX
|
131 M | $ 19.52 | 1.93 % | $ 9.96 B | ||
|
Luminex Corporation
LMNX
|
21.1 M | - | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
59.8 K | - | -9.52 % | $ 20.6 M | ||
|
Ekso Bionics Holdings
EKSO
|
1.96 M | $ 4.68 | 0.21 % | $ 94.4 M | ||
|
Antares Pharma, Inc.
ATRS
|
3.94 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
26.2 M | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
26.8 K | - | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
110 M | - | -0.05 % | $ 10.3 B | ||
|
Harvard Bioscience
HBIO
|
4.51 M | $ 0.71 | -4.45 % | $ 30.1 M | ||
|
Varian Medical Systems, Inc.
VAR
|
782 M | - | -0.02 % | $ 16.3 B | ||
|
ICU Medical
ICUI
|
30.4 M | $ 148.28 | -0.1 % | $ 3.62 B | ||
|
iRhythm Technologies
IRTC
|
2.93 M | $ 170.21 | 0.82 % | $ 5.31 B | ||
|
Alcon
ALC
|
581 M | $ 79.15 | 0.43 % | $ 40.4 B | ||
|
Repro Med Systems
KRMD
|
125 K | $ 5.8 | 0.35 % | $ 264 M | ||
|
AngioDynamics
ANGO
|
200 K | $ 13.42 | 2.13 % | $ 548 M | ||
|
The Cooper Companies
COO
|
128 M | $ 81.36 | -0.88 % | $ 16.2 B | ||
|
LeMaitre Vascular
LMAT
|
552 K | $ 83.04 | -1.14 % | $ 1.86 B | ||
|
Masimo Corporation
MASI
|
95.5 M | $ 137.35 | -0.72 % | $ 7.32 B | ||
|
Haemonetics Corporation
HAE
|
43.3 M | $ 80.24 | -3.89 % | $ 4.04 B | ||
|
Merit Medical Systems
MMSI
|
572 K | $ 86.49 | -0.24 % | $ 5.04 B | ||
|
Intuitive Surgical
ISRG
|
469 M | $ 559.7 | 3.2 % | $ 199 B | ||
|
OraSure Technologies
OSUR
|
3 M | $ 2.49 | - | $ 185 M | ||
|
Microbot Medical
MBOT
|
16.8 K | $ 2.23 | -7.65 % | $ 22.7 M | ||
|
Milestone Scientific
MLSS
|
340 K | $ 0.36 | -7.4 % | $ 28.7 M | ||
|
Nephros
NEPH
|
70 K | $ 4.98 | -0.8 % | $ 51.7 M | ||
|
NeuroMetrix
NURO
|
1.96 M | - | 5.05 % | $ 9.02 M | ||
|
ResMed
RMD
|
109 M | $ 251.67 | -0.27 % | $ 36.8 B | ||
|
Envista Holdings Corporation
NVST
|
146 M | $ 22.07 | 0.46 % | $ 3.8 B | ||
|
Pro-Dex
PDEX
|
202 K | $ 44.0 | 1.43 % | $ 145 M | ||
|
STERIS plc
STE
|
160 M | $ 253.98 | 0.82 % | $ 25 B | ||
|
Stereotaxis
STXS
|
6.66 M | $ 2.35 | -1.05 % | $ 190 M | ||
|
Pulse Biosciences
PLSE
|
16 K | $ 14.04 | -1.4 % | $ 674 M | ||
|
Predictive Oncology
POAI
|
305 K | - | - | $ 32.4 M | ||
|
Repligen Corporation
RGEN
|
17.1 M | $ 160.09 | 1.72 % | $ 8.92 M | ||
|
DENTSPLY SIRONA
XRAY
|
95 M | $ 11.43 | -1.21 % | $ 2.32 B | ||
|
Retractable Technologies
RVP
|
377 K | $ 0.84 | 1.99 % | $ 25.1 M | ||
|
West Pharmaceutical Services
WST
|
49.6 M | $ 271.82 | 1.6 % | $ 19.8 B |